Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

RadNet, Inc. Common Stock (RDNT)
RadNet, Inc. Common Stock
XNAS:RDNT
82.79
0.00%

Ask
$83.41 - 100.00
Bid
$82.12 - 600.00
Low
$81.68
High
$83.45
Open
$83.23
Prev Close
$82.79
52W High
85.84
52W Low
45
Volume
557814
Avg Vol (3m)
881758.1
Float
69249296.15
Chart
TendieTensor AI Analysis

Company
Asset Type: Common Stock
SIC Code: 8071
Sector: Health Services
Industry: Medical/Nursing Services
Date Listed: 10/31/1994
Primary Exchange: XNAS

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.

Phone: (310) 478-7808
Address: 1510 Cotner Ave
City: Los Angeles
State: CA
Postal Code: 90025
TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
11,021
P/E (TTM)
-465.640000
P/B (TTM)
6.024800
EPS
0.2
Round Lot
100
Composit FIGI
BBG000CXSF54
Share Class FIGI
BBG001S75DK5
Share Class Shares Outstanding
76.92M
Weighted Shares Outstanding
77.10M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own RDNT. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.